The Lancet in conversation with
Jessamy Bagenal, Chloe Wilson, and Callum Davidson—editors at The Lancet—and Gavin Cleaver, The Lancet Group’s Audio Producer, in conversation with the journal’s authors, explore their latest research and its impact on people’s health, healthcare, and health policy.
A monthly audio companion to the journal, this podcast covers topics that advance the field of medical research, from exploring treatments to examining drug trials, public health outbreaks to surgical techniques, and more.
Podcasting since 2020 • 38 episodes
The Lancet in conversation with
Latest Episodes
Susannah Stanway on the London Global Cancer Week
In Conversation with The Lancet returns with Dr Susannah Stanway, honorary consultant medical oncologist at the Royal Marsden and honorary clinical senior lecturer in Education at the Institute of Cancer Research, reflecting on London Global Ca...
•
24:04
Carlos Monteiro, Camila Corvalán, and Phil Baker on Ultra-Processed Foods and Human Health
Ultra-processed foods are on the rise. Despite the emphasis placed on individual responsibility, our deteriorating diets are primarily the result of the sophisticated political tactics of a powerful global ultra-processed food industry. Address...
•
1:01:17
Presented at ASH: the EPCORE FL-1 study on epcoritamab in follicular lymphoma
Franck Morschhauser joins Ben Abbott of The Lancet to discuss the phase 3 EPCORE FL-1 study on epcoritamab, lenalidomide, and rituximab for relapsed or refractory follicular lymphoma, which is being presented at ASH 2025.Click h...
•
13:03
Presented at ESMO: the HARMONi-6 study on a bispecific antibody therapy for squamous NSCLC
Shun Lu joins Ben Abbott of The Lancet to discuss the phase 3 HARMONi-6 trial of ivonescimab plus chemotherapy as first-line treatment in advanced squamous non-small-cell lung cancer, which is being presented at ESMO 2025.
•
20:43
Presented at ESMO: the POTOMAC study on immunotherapy in non-muscle-invasive bladder cancer
Neal Shore joins Ben Abbott of The Lancet to discuss the phase 3 POTOMAC trial of durvalumab plus BCG in BCG-naïve, high-risk non-muscle-invasive bladder cancer, which is being presented at ESMO 2025.
•
22:09